表紙
市場調查報告書

全球醫藥品受託製造市場:2019年∼2029年 - 醫藥品原料藥 (API)/最後製劑 (FDF)、非專利API、HPAPI (高活性原體)、固態製劑、注射用製劑

Pharmaceutical Contract Manufacturing Market 2019-2029: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

出版商 Visiongain Ltd 商品編碼 214197
出版日期 內容資訊 英文 231 Pages
商品交期: 最快1-2個工作天內
價格
全球醫藥品受託製造市場:2019年∼2029年 - 醫藥品原料藥 (API)/最後製劑 (FDF)、非專利API、HPAPI (高活性原體)、固態製劑、注射用製劑 Pharmaceutical Contract Manufacturing Market 2019-2029: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages
出版日期: 2019年08月19日內容資訊: 英文 231 Pages
簡介

全球醫藥品受託製造的市場規模今後預計將以5.7%的年複合成長率 (CAGR) 擴大,2024年達到1380億美元的規模。

本報告提供全球醫藥品受託製造市場相關分析,整體市場規模趨勢預測 (今後11年份) ,及次市場詳細趨勢,主要國家 (已開發國家/新興國家)的市場結構、趨勢,主要的推動及阻礙市場要素,主要企業的簡介等系統性資訊。

第1章 報告概要

第2章 醫藥品受託製造:簡介

  • 所謂醫藥品受託製造
  • 醫藥品市場上外包的優點
  • 醫藥品受託製造服務
  • 策略和策略:外包的重要性
  • 醫藥品受託製造趨勢
  • 醫藥品受託製造:市場區隔

第3章 醫藥品受託製造:全球市場

  • 醫藥品受託製造市場
  • 醫藥品受託製造:市場整體預測
    • 市場佔有率的變化 (今後11年份)
    • 促進市場成長的要素
    • 是學名藥:促進因素,還是阻礙因素?
    • 其他的醫藥品受託製造服務市場:展望與預測 (今後11年份)
      • 處方開發服務的需求增加

第4章 API (醫藥品原料藥) 受託製造服務市場

  • API受託製造市場
  • API受託製造市場:展望與預測 (今後11年份)
    • 市場趨勢預測 (今後11年份)
    • 推動及阻礙市場要素
  • 非專利API受託製造市場:展望與預測 (今後11年份)
  • HPAPI (高活性原體) 受託製造市場 (今後11年份)

第5章 FDF (最後製劑) 受託製造服務市場

  • FDF受託製造市場
  • FDF受託製造市場預測 (今後11年份)
  • 固態製劑受託製造市場 (今後11年份)
  • 注射用製劑受託製造市場 (今後11年份)

第6章 醫藥品受託製造:先進國家市場

  • 已開發國家的醫藥品受託製造市場
  • 美國市場
    • 市場法規
    • 未來預測 (今後11年份) 等
  • 加拿大市場
  • 歐洲市場 (德國、法國、義大利、西班牙、英國)
  • 日本市場

第7章 醫藥品受託製造:新興國家市場

  • 新興國家醫藥品受託製造市場
  • 中國市場
  • 印度市場
  • 巴西市場
  • 俄羅斯市場
  • 韓國市場
  • 土耳其市場
  • 墨西哥市場

第8章 醫藥品受託製造市場主要企業

  • 主要的受託製造機關 (CMO)
  • Catalent
    • 企業概要,未來展望等
  • Lonza
  • Evonik Degussa
  • DPx Holdings - DSM and Patheon
  • Teva
  • Boehringer Ingelheim BioXcellence
  • Famar
  • Fareva
  • Vetter Pharma
  • Mylan

第9章 醫藥品受託製造產業趨勢:CMO的觀點的定性分析

  • 優勢和弱點
  • 機會及威脅
  • STEP分析:社會要素,技術性趨勢,經濟壓力,政治課題
  • 醫藥品開發趨勢:CMO的影響
  • CMO產業的發展前景
  • 製造工程的發展預測

第10章 醫藥品受託製造產業趨勢:客戶觀點的定性分析

  • 優勢和弱點
  • 機會及威脅
  • 有關外包的決策的重要方面
  • 外包聯盟趨勢預測

第11章 結論

  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0471

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 5.7% in the first half of the forecast period. The API Manufacturing submarket held 67% of the market in 2018. Visiongain estimated that the pharmaceutical contract manufacturing market will reach $138bn in 2024.

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 231-page report you will receive 73 tables and 55 figures - all unavailable elsewhere.

The 231-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Pharmaceutical Contract Manufacturing Market forecasts from 2019-2029
  • Submarket forecasts at world level, from 2019-2029:
  • Active pharmaceutical ingredients (APIs) , with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
  • Finished dosage formulations (FDFs) , with sub forecasts for solid dose forms, injectable dosages and other dosage types
  • Other applications of outsourced production - other related services

Revenue forecasts from 2019-2029, for these regional and national markets:

  • The US
  • Canada
  • Japan
  • EU5: Germany, France, the UK, Italy and Spain
  • BRIC: Brazil, Russia, India, China
  • South Korea
  • Turkey
  • Mexico
  • Others

Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

Qualitative Analysis from a CMO Perspective

Qualitative Analysis from a Client Perspective

Key questions answered by this report:

  • What is the current size of the total global pharmaceutical contract manufacturing market?
  • How much will this market be worth from 2018 to 2029?
  • How is the pharmaceutical contract manufacturing market evolving?
  • What is driving and restraining the pharmaceutical contract manufacturing market?
  • What are the market shares of each segment of the overall pharmaceutical contract manufacturing market currently and how will these change to 2029?
  • What are the main submarkets and how much revenue will each pharmaceutical contract manufacturing submarket account for over the next 10 years to 2029 and why?
  • How will the market shares for each pharmaceutical contract manufacturing submarket develop from 2018 to 2029?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve to 2029?
  • What are the largest national markets for pharmaceutical contract manufacturing? What is the current status and how will it develop over the next ten years? What are their forecasts for 2019-2029?
  • Who are the most prominent companies, and what are their activities and outlooks?
  • What are the main trends that will affect the pharmaceutical contract manufacturing market between 2018 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the pharmaceutical contract manufacturing market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2019-2029: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Pharmaceutical Contract Manufacturing Market Segmentation
  • 1.2 Global Pharmaceutical Contract Manufacturing Market Overview
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing

  • 2.1 What is Pharmaceutical Contract Manufacturing?
  • 2.2 The Benefits of Outsourcing in the Pharmaceutical Market
  • 2.3 Pharmaceutical Contract Manufacturing Services
  • 2.4 Strategy and Tactics: The Importance of Outsourcing Wisely
  • 2.5 Trends in Contract Manufacturing, 2018-2029
  • 2.6 Pharmaceutical Contract Manufacturing: Market Segmentation

3. Pharmaceutical Contract Manufacturing: World Market 2019-2029

  • 3.1 Pharmaceutical Contract Manufacturing Market:
    • 3.1.1 Contract Manufacturing is the Most Mature Pharma Outsourcing Sector
    • 3.1.2 The Pharma Contract Manufacturing Market by Sector 2018
  • 3.2 Pharma Contract Manufacturing: Overall Market Forecast 2019-2029
    • 3.2.1 Changing Market Shares by Segment 2018-2029
    • 3.2.2 Drivers for Growth in the Contract Manufacturing Market to 2029
    • 3.2.3 Generics: A Driver or Restraint?
    • 3.2.4 Other Contract Manufacturing Services Market: Outlook and Forecast, 2019-2029
  • 3.2.4.1 Increasing Demand for Formulation Development Services

4. The Contract API Manufacturing Services Submarket 2019-2029

  • 4.1 The Contract API Manufacturing Submarket
    • 4.1.1 Chemical APIs Will Experience Resurgence after the Shift of Focus to Biological APIs
    • 4.1.2 The API Manufacturing Submarket by Sector, 2018
  • 4.2 The Contract API Manufacturing Submarket: Outlook and Forecast 2019-2029
    • 4.2.1 Drivers for Growth in the API Submarket to 2029
    • 4.2.2 The Potential for Microreactors in Commercial Manufacturing to 2029
    • 4.2.3 How Will New EU Regulations Impact the API Manufacturing Submarket?
    • 4.2.4 Contract API Manufacturing Submarket Restraint 2019-2029
      • 4.2.4.1 Backwards Integration for Generics Manufacturers
  • 4.3 The Contract Generic API Manufacturing Submarket 2019-2029
    • 4.3.1 The Contract Generic API Manufacturing Submarket Forecast 2019-2029
    • 4.3.2 The Contract Generic API Manufacturing Submarket Drivers and Restraints to 2029
      • 4.3.2.1 The US Generic Drug User Fee Act and API Manufacturing
  • 4.4 The Contract HPAPI Manufacturing Submarket 2015-2028
    • 4.4.1 Challenges and Opportunities in High Containment Manufacturing
    • 4.4.2 Company Investment into HPAPI Manufacturing Facilities: Growth Increases in the HPAPI Manufacturing Sector
    • 4.4.3 The Contract HPAPI Manufacturing Submarket Forecast 2018-2029
    • 4.4.4 The Contract HPAPI Manufacturing Submarket Drivers and Restraints to 2029

5. The Contract FDF Manufacturing Services Submarket 2019-2029

  • 5.1 The Contract FDF Manufacturing Submarket, 2018
    • 5.1.1 Solid Dosage Manufacturing Leads the Market
    • 5.1.2 CMOs Report High Demand for Softgel Formulations
  • 5.2 The Contract FDF Manufacturing Submarket Forecast 2019-2029
    • 5.2.1 Complex Molecule Manufacturing Will Drive Growth to 2029
    • 5.2.2 What Will Restrain Growth in FDF Outsourcing?
  • 5.3 The Contract Solid Dosage Manufacturing Submarket 2019-2029
    • 5.3.1 How Will Revenue for Solid Dosage Manufacturing Grow to 2029?
    • 5.3.2 The Solid Dosage Manufacturing Submarket Drivers and Restraints 2019-2029
      • 5.3.2.1 Will Product Reformulation Drive Growth to 2029?
  • 5.4 The Contract Injectable Dosage Manufacturing Submarket 2019-2029
    • 5.4.1 The Contract Injectable Dosage Manufacturing Submarket Forecast 2019-2029
      • 5.4.1.1 Drug Shortages Offer Opportunity to CMOs in the Short-Term
    • 5.4.2 Demand for Biopharma Manufacturing Will Drive Growth 2019-2029
      • 5.4.2.1 Interest in Antibody-Drug Conjugate Development Is Growing
      • 5.4.2.3 Challenges in Manufacturing Antibody-Drug Conjugates
    • 5.4.3 Lyophilisation and Aseptic Filling Demand Will Rise
      • 5.4.3.1 Will Spray Drying Replace Lyophilisation in FDF Manufacturing?

6. Leading National Markets for Pharmaceutical Contract Manufacturing 2019-2029

  • 6.1 Leading National Markets for Pharmaceutical Contract Manufacturing, 2018
    • 6.1.1 Challenges in Assessing the Market: Supply versus Demand
    • 6.1.2 Leading National Pharmaceutical Contract Manufacturing Markets: Revenue Forecasts 2019-2029
    • 6.1.3 Pharmaceutical Manufacturing in the US: Regulatory Oversight, 2018
    • 6.1.4 Controlling Foreign Manufacturing Sites
    • 6.1.5 What Impact Will the GDUFA 2012 Have on Foreign Manufacturing?
    • 6.1.6 Outsourcing and US Manufacturing Regulations
    • 6.1.7 Increased Demand for Domestic API Manufacturing?
  • 6.2 The US Contract Manufacturing Market Forecast 2019-2029
  • 6.3 Canada Contract Manufacturing Market Forecast 2019-2029
  • 6.4 Outlook for Pharmaceutical Contract Manufacturing in the EU
    • 6.4.1 The EU is the Leading Destination for Pharmaceutical Contract Manufacturing
    • 6.4.2 Regulatory Aspects of Pharma Manufacturing in the EU
      • 6.4.2.1 The European Commission Amends Annex 16
      • 6.4.2.2 The Falsified Medicine Directive: Controlling API Imports
    • 6.4.3 Biopharma Manufacturing Demand Will Rise
    • 6.4.4 The EU Contract Manufacturing Market Forecast 2019-2029
    • 6.4.5 Germany: The Leading EU Destination for API and FDF Manufacturing
      • 6.4.5.1 Demand for Contract Manufacturing in Germany: Revenue Forecast 2019-2029
    • 6.4.6 CMOs Account for a Third of Manufacturing Sites in France
      • 6.4.6.1 French Pharma Contract Manufacturing Market Forecast 2019-2029
    • 6.4.7 Italy: Strong API Manufacturing Traditions
      • 6.4.7.1 Revenue Forecast for the Italian Pharma Contract Manufacturing Market 2019-2029
    • 6.4.8 Spain: How Will Demand for Manufacturing Services Grow?
    • 6.4.9 UK: Pharmaceutical Contract Manufacturing Market Forecast 2019-2029
  • 6.5 Pharma Contract Manufacturing in Japan to 2029
    • 6.5.1 Pharmaceutical Manufacturing Regulations in Japan
      • 6.5.1.1 The Pharmaceutical Affairs Law
    • 6.5.2 Greater API Outsourcing to Drive Japanese Market Growth to 2028 In Spite of Currency Devaluation Weakening the Economy

7. Leading Emerging Markets for Pharmaceutical Contract Manufacturing Market 2019-2029

  • 7.1 Pharmaceutical Contract Manufacturing in Developing Countries
    • 7.1.1 Outsourcing to Emerging National Markets from Developed Markets
      • 7.1.1.1 Demand Will Increase for Services in India and China
    • 7.1.2 Domestic Demand for Pharmaceutical Contract Manufacturing Services
    • 7.1.3 Pharmaceutical Contract Manufacturing: Leading Emerging National Market Forecasts 2019-2029
  • 7.2 Chinese Demand for Pharma Contract Manufacturing Services 2019-2029
    • 7.2.1 Improved Manufacturing Regulations in China
      • 7.2.1.1 Regulations for Excipients and Guidance for API Manufacturing
  • #REF!
    • 7.2.2 Chinese CMOs Are Investing in Biopharma Manufacturing
    • 7.2.3 China Pharma Contract Manufacturing Market Forecast 2019-2029
  • 7.3 India: CMOs with Strong Infrastructure and Growing Expertise
    • 7.3.1 Regulatory Outlook for Indian Pharma Manufacturing
      • 7.3.1.1 Stricter Quality Standards to Ensure Compliance with EU Rules
    • 7.3.2 Domestic Manufacturing Dominates the Indian Pharma Market
    • 7.3.3 Demand for Contract Manufacturing in India: Market Forecast 2019-2029
  • 7.4 Brazil: Contract Manufacturing Outlook 2019-2029
    • 7.4.1 Pharmaceutical Manufacturing Regulations in Brazil
      • 7.4.1.1 Guidelines and Regulations Proposed
    • 7.4.2 Brazil Imports Most of its APIs
    • 7.4.3 Brazil: Pharma Contract Manufacturing Market Forecast 2019-2029
  • 7.5 The Russian Pharma Contract Manufacturing Market 2019-2029
    • 7.5.1 Pharma Manufacturing Regulations in Russia
      • 7.5.1.1 Compliance with GMP in Russia
    • 7.5.2 How Will Demand for Contract Manufacturing Grow in Russia to 2029?
  • 7.6 South Korea: Government Supported Growth
    • 7.6.1 South Korea: Strict GMP Regulations
    • 7.6.2 South Korea: Pharma Contract Manufacturing Market Forecast 2019-2029
  • 7.7 Turkey: Domestic Market to offer Huge Growth Opportunities
    • 7.7.1 Turkey: An Important Hub for Global Pharma Companies
    • 7.7.2 Drug Approvals Delaying Growth of the Turkey Pharma Market
    • 7.7.3 Turkey: Pharma Contract Manufacturing Market Forecast 2019-2029
  • 7.8 Mexico: Emerging Market Power
    • 7.8.1 Healthcare - A Top Priority in Mexico
    • 7.8.2 Strategic Management of High Expectations
    • 7.8.3 Mexico: Pharma Contract Manufacturing Market Forecast 2019-2029

8. Leading Companies in the Pharmaceutical Contract Manufacturing Market

  • 8.1 Leading CMOs in the Pharmaceutical Contract Manufacturing Market
  • 8.2 Catalent: Leading CMO
    • 8.2.1 Multiple Expansions and Increased Focus on Biologic Manufacturing
    • 8.2.2 Recent Developments
  • 8.3 Lonza: Potential to Lead in ADC Manufacturing
    • 8.3.1 Lonza: Expanding its Capacities to Meet Customer Demand for Biologic Manufacturing
  • 8.3.2 Recent Developments
  • 8.4 Evonik Degussa: Specialising in Small Molecules
    • 8.4.1 Recent Developments
  • 8.5 DPx Holdings - DSM and Patheon: Recent Merger Has Strengthened Their Position
    • 8.5.1 Increasing Capacity Tactically and Expanding Worldwide
  • 8.6 Teva: The World's Largest API Manufacturer
    • 8.6.1 Will Teva Expand into Emerging Markets?
  • 8.6.2 Recent Developments
  • 8.7 Boehringer Ingelheim BioXcellence: Boehringer's Biopharma Manufacturing Division
    • 8.7.1 Recent Developments
    • 8.7.2 Adding New Services for Growth
  • 8.8 Famar: A Possible Candidate for Acquisition
    • 8.8.1 Recent Developments
  • 8.9 Fareva: A Strategic Shift from Acquisition to Increase in Capacity
  • 8.10 Vetter Pharma: Specialists in Aseptic Filling, Lyophilisation and Siliconisation
    • 8.10.1 Vetter's Growth: Increasing in Capacity and Market Expansion
  • 8.11 Mylan: A World Leader in Generics Manufacturing
    • 8.11.1 Recent Developments

9. Pharmaceutical Contract Manufacturing Industry Trends: Qualitative Analysis from a CMO Perspective 2019-2029

  • 9.1 Pharma Contract Manufacturing Market: Strengths and Weaknesses from a CMO Perspective 2019-2029
  • 9.2 Pharma Contract Manufacturing Market: Opportunities and Threats from a CMO Perspective 2019-2029
  • 9.3 Pharma Contract Manufacturing Market: STEP Analysis 2019-2029
    • 9.3.1 Social Factors
    • 9.3.2 New Technologies Will Drive Market Growth to 2029
      • 9.3.2.1 Advantages of Single-Use Technologies in Biopharma Manufacturing
      • 9.3.2.2 Green Technology in Contract Manufacturing
      • 9.3.2.3 Drug Delivery Trends and CMOs
      • 9.3.2.4 Biologics Are Causing Increased Demand for Lyophilisation
      • 9.3.2.5 Improving Solubility and Stability for Small Molecules
      • 9.3.2.6 Spray Drying as an Advantageous Alternative to Lyophilisation
      • 9.3.2.7 Hot-Melt Extrusion: A Niche Opportunity
    • 9.3.3 Economic Pressures
      • 9.3.3.1 Developed-Market CMOs Facing Competition from Emerging Markets
    • 9.3.4 Political Issues
      • 9.3.4.1 How Will Regulatory Developments Affect CMOs?
  • 9.4 Trends in Drug Development Affecting CMOs to 2028
    • 9.4.1 Orphan Drug Development: Smaller Manufacturing Capacities
    • 9.4.2 Complex Biologics: Interest in ADCs is increasing
    • 9.4.3 How Will Biosimilar Market Growth Affect CMOs?
  • 9.4.4 The Future of Small Molecule Outsourcing
  • 9.5 How Will CMOs Expand in the Coming 10 Years?
    • 9.5.1 CMO Consolidation Will Increase
    • 9.5.2 There Will Be More Manufacturing Facilities Available for Acquisition
  • 9.6 Developments in the Manufacturing Process
    • 9.6.1 Rising Interest from Companies in Quality by Design (QbD)
    • 9.6.2 A Move Towards Continuous Manufacturing

10. Pharmaceutical Contract Manufacturing Trends: Qualitative Analysis of the Pharmaceutical Contract Manufacturing Market from a Client Perspective 2019-2029

  • 10.1 Pharma Contract Manufacturing Market: Strengths and Weaknesses from a Client Perspective 2019-2029
  • 10.2 Pharma Contract Manufacturing Market: Opportunities and Threats from a Client Perspective 2019-2029
  • 10.3 Important Aspects of the Outsourcing Decision
    • 10.3.1 What Factors Will Influence CMO Selection?
    • 10.3.2 CMO - Pharma Partnering Models
    • 10.3.3 Strategic Partnering
    • 10.3.4 Selecting a Local CMO vs. Offshoring
    • 10.3.5 CMOs in Emerging Markets
    • 10.3.6 Good Communication is Vital for Success
    • 10.3.7 Ensuring Protection in Intellectual Property and Tech Transfer
    • 10.3.8 Regulatory Compliance is a Key Deciding Factor for Pharma Clients
      • 10.3.8.1 Regulatory Bodies and Outsourcing
      • 10.3.8.2 Quality Agreement
      • 10.3.8.3 Global Harmonisation Will Improve Compliance
  • 10.4 Trends in Outsourcing Partnerships 2019-2029
    • 10.4.1 Big Pharma and Outsourced Manufacturing
    • 10.4.2 Small and Virtual Pharma Companies
    • 10.4.3 How Will Biotech Funding Impact the Pharma Contract Manufacturing Industry to 2029?

11. Conclusions

  • 11.1 The World Pharmaceutical Contract Manufacturing Market
  • 11.2 Outlook for the Market to 2029
    • 11.2.1 Rising Demand for High Value Services 2018-2029
    • 11.2.2 Demand Will Be Highest Among Developed-Market Clients
  • 11.3 Which New Technologies Will Stimulate Demand to 2029?
  • Appendices
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 3.1 Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2018
  • Table 3.2 Pharmaceutical Contract Manufacturing Market: Overall Market Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 3.3 Pharma Contract Manufacturing Market: Market Shares (%), 2018-2023
  • Table 3.4 Pharma Contract Manufacturing Market: Market Shares (%), 2024-2029
  • Table 3.5 Other Services Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 4.1 Contract API Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2018
  • Table 4.2 Contract API Manufacturing Submarket: Overall Submarket Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.3 Contract API Manufacturing Submarket Shares (%), 2018-2023
  • Table 4.4 Contract API Manufacturing Submarket Shares (%), 2023-2029
  • Table 4.5 Contract API Manufacturing Submarket: Drivers and Restraints, 2018-2029
  • Table 4.6 Contract Generic API Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.7 Contract Generic API Manufacturing Submarket: Drivers and Restraints, 2019-2029
  • Table 4.8 Contract HPAPI Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 4.9 Contract HPAPI Manufacturing Submarket: Drivers and Restraints, 2019-2029
  • Table 5.1 Contract FDF Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2018
  • Table 5.2 Contract FDF Manufacturing Submarket: Overall Submarket Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 5.3 Contract FDF Manufacturing Submarket: Segment Shares (%), 2018-2023
  • Table 5.4 Contract FDF Manufacturing Submarket: Segment Shares (%), 2023-2029
  • Table 5.5 Contract FDF Manufacturing Submarket: Drivers and Restraints, 2019-2029
  • Table 5.6 Contract Solid Dosage Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%) 2019-2029
  • Table 5.7 Contract Solid Dosage Manufacturing Submarket: Drivers and Restraints, 2018-2029
  • Table 5.8 Contract Injectable Dosage Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%) 2019-2029
  • Table 5.9 Contract Injectable Dosage Manufacturing Submarket: Drivers and Restraints, 2019-2029
  • Table 5.10 Selected ADCs in Development, 2018
  • Table 5.11 Selected CMOs Investing in ADC Manufacturing Capacity, 2018
  • Table 6.1 Pharma Contract Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2018
  • Table 6.2 Pharma Contract Manufacturing Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.3 Pharmaceutical Contract Manufacturing Market: Submarket Shares (%), 2018-2023
  • Table 6.4 Pharmaceutical Contract Manufacturing Market: Submarket Shares (%), 2023-2029
  • Table 6.5 GDUFA: Annual Fees for Domestic and Foreign Manufacturing Sites, 2015-2016
  • Table 6.6 US Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 6.7 Canada Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 6.8 EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2018
  • Table 6.9 EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2023
  • Table 6.10 EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2029
  • Table 6.11 EU5 Pharma Contract Manufacturing Market: National Market Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 6.12 German Pharma Contract Manufacturing: Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 6.13 Selected French Manufacturing Site Acquisitions, 2009-2013
  • Table 6.14 French Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.15 Italian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.16 Spanish Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.17 UK Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 6.18 Japanese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.1 Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2018
  • Table 7.2 Pharma Contract Manufacturing Market: Leading Emerging Market Forecasts ($bn), Annual Growth (%), CAGR (%), 2018-2029
  • Table 7.3 Pharma Contract Manufacturing Market: Emerging Market Shares (%), 2018-2023
  • Table 7.4 Pharma Contract Manufacturing Market: Emerging Market Shares (%), 2023-2029
  • Table 7.5 Chinese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.6 Indian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.7 Brazilian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.8 Russian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.9 South Korean Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.10 Turkey Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 7.11 Mexico Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2029
  • Table 8.1 Catalent: Revenue ($bn), Annual Growth, CAGR, 2013-2018
  • Table 8.2 Lonza: Revenue (CHF bn), Annual Growth (%), CAGR (%), 2013-2018
  • Table 8.3 Teva: Revenue ($bn), Annual Growth (%), CAGR (%), 2012-2017
  • Table 8.4 Boehringer Ingelheim BioXcellence: Revenue (CHF bn), Annual Growth (%), CAGR (%), 2012-2017
  • Table 9.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2019-2029
  • Table 9.2 Pharma Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2019-2029
  • Table 9.3 Pharma Contract Manufacturing Market: STEP Analysis, 2019-2029
  • Table 9.4 Selected Lyophilisation Service Providers
  • Table 9.5 Lyophilisation vs. Spray Drying: A Comparison
  • Table 9.6 Selected Biological Manufacturing Expansion, 2013-2018
  • Table 9.7 Selected EU-Approved Biosimilars: Manufacturers and Companies, 2018
  • Table 9.8 Selected CMOs Growing Faster than the Market, 2007-2012
  • Table 9.9 Regional Market Expansion, 2010-2017
  • Table 10.1 Pharma Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2019-2029
  • Table 10.2 Pharma Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2019-2029
  • Table 10.3 Benefits and Risks to Outsourcing Pharma Manufacturing
  • Table 10.4 ICH Guidelines: Key Facts and Adoption, 2000-2014
  • Table 12.1 Pharma Contract Manufacturing Market: Revenue ($bn), CAGR (%), and Market Share (%) by Sector, 2018, 2023 and 2029
  • Table 12.2 Pharma Contract Manufacturing Market: Revenue ($bn), CAGR (%), and Market Share (%) by Region, 2018, 2023 and 2029

List of Figures

  • Figure 1.1 Global Pharmaceutical Contract Manufacturing Market Segmentation Overview, 2019
  • Figure 2.1 Selected Services Offered by CMOs
  • Figure 2.2 Major Trends Affecting Pharma Contract Manufacturing Revenue Growth, 2018-2029
  • Figure 3.1 Pharma Contract Manufacturing: Market Share (%) by Sector, 2018
  • Figure 3.2 Pharmaceutical Contract Manufacturing Market: Overall Market Forecast, Revenue ($bn), 2018-2029
  • Figure 3.3 Pharma Contract Manufacturing Market: Shares (%), 2024
  • Figure 3.4 Pharma Contract Manufacturing Market: Shares (%), 2029
  • Figure 3.5 Pharma Contract Manufacturing Market: Drivers, 2018-2029
  • Figure 3.6 Pharma Contract Manufacturing Market: Restraints, 2018-2029
  • Figure 3.7 Other Services Submarket Forecast, Revenue ($bn), 2018-2029
  • Figure 4.1 Contract API Manufacturing Submarket: Segment Shares (%) by Sector, 2018
  • Figure 4.2 Contract API Manufacturing Submarket Forecast, Revenue ($bn), 2019-2029
  • Figure 4.3 Contract API Manufacturing Submarket: Segment Shares (%), 2023
  • Figure 4.4 Contract API Manufacturing Submarket: Segment Shares (%), 2029
  • Figure 4.5 Contract Generic API Manufacturing Submarket Forecast, Revenue ($bn), 2019-2029
  • Figure 4.6 Contract HPAPI Manufacturing Submarket Forecast, Revenue ($bn), 2018-2029
  • Figure 5.1 Contract FDF Manufacturing Submarket: Segment Shares (%) by Sector, 2018
  • Figure 5.2 Contract FDF Manufacturing Submarket Forecast, Revenue ($bn), 2019-2029
  • Figure 5.3 Contract FDF Manufacturing Submarket: Segment Shares (%), 2023
  • Figure 5.4 Contract FDF Manufacturing Submarket: Segment Shares (%), 2029
  • Figure 5.5 Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2019-2029
  • Figure 5.6 Contract Injectable Dosage Manufacturing Submarket Forecast, Revenue ($bn), 2019-2029
  • Figure 6.1 Pharma Contract Manufacturing Market: Share (%) by Region, 2018
  • Figure 6.2 Pharmaceutical Contract Manufacturing Market: Share (%) by Region, 2023
  • Figure 6.3 Pharmaceutical Contract Manufacturing Market: Share (%) by Region, 2029
  • Figure 6.4 US Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2018-2029
  • Figure 6.5 Canada Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2018-2029
  • Figure 6.6 EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2018
  • Figure 6.7 EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2023
  • Figure 6.8 EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2029
  • Figure 6.9 EU5 Pharma Contract Manufacturing Market, Revenue ($bn), 2018-2029
  • Figure 6.10 German Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2018-2029
  • Figure 6.11 French Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 6.12 Italian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2018-2029
  • Figure 6.13 Spanish Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 6.14 UK Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 6.15 Japanese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 7.1 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2018
  • Figure 7.2 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2023
  • Figure 7.3 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2029
  • Figure 7.4 Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2018, 2023 and 2029
  • Figure 7.5 Chinese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 7.6 Indian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 7.7 Brazilian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 7.8 Russian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 7.9 South Korean Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 7.10 Turkey Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 7.11 Mexico Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2019-2029
  • Figure 8.1 Catalent: Revenue ($bn), 2012-2017
  • Figure 8.2 Lonza: Revenue (CHF bn), 2013-2018
  • Figure 8.3 Teva: Revenue ($bn), 2013-2018
  • Figure 8.4 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2012-2017
  • Figure 10.1 Overview of Approved ICH Manufacturing Guidelines
  • Figure 12.1 Pharma Contract Manufacturing Market: Revenue ($bn) by Sector, 2018, 2023 and 2029
  • Figure 12.2 Pharma Contract Manufacturing Market: Revenue ($bn) by Region, 2018, 2023 and 2029

List of Companies Mentioned in the Report:

  • AbbVie
  • Actavis
  • ADC Biotechnology
  • Aegerion Pharmaceuticals
  • Aenova Group
  • Aesica Pharma
  • Agensys
  • Agila Specialties
  • Ajinomoto Althea Inc
  • Alexion Pharmaceuticals
  • Almac Group
  • Althea Technologies
  • AMRI (Albany Molecular Research Inc)
  • API Corporation (APIC)
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Banner Life Sciences
  • Banner Pharmacaps
  • Baring Private Equity Asia
  • Bausch & Lomb
  • Bayer Healthcare
  • Ben Venue Laboratories
  • Bend Research
  • Biogen Idec
  • BioIndustry Association (BIA)
  • Biotest
  • Blackstone Group
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence
  • Bristol-Myers Squibb Company
  • Bushu Pharmaceuticals
  • Cambrex
  • Cambridge Major Laboratories
  • Catalent Pharma Solutions
  • Cedarburg Hauser
  • Cell Therapy Catapult
  • Celldex Therapeutics
  • Celltrion
  • Cenexi
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Chemtrix
  • China FDA (CFDA)
  • Cipla
  • Cook Pharmica
  • CordenPharma
  • CTC Bio
  • Daito Pharmaceutical
  • Delpharm
  • Dishman Pharmaceuticals
  • DPx Fine Chemicals
  • DPx Holdings B.V.
  • Dr. Reddy's Laboratories
  • DSP (DSM Sinochem Pharmaceuticals)
  • Eisai
  • Eli Lilly
  • Esteve Quimica
  • Euticals
  • Evonik Degussa
  • Famar
  • Fareva
  • FUJIFILM Diosynth Biotechnologies,
  • Gallus Biopharmaceutical, LLC.
  • G-CON
  • GEA Pharma-Systems
  • Genentech
  • GlaxoSmithKline (GSK)
  • Granules India
  • Haupt Pharma
  • Hexal
  • Hospira
  • Hospira One2One
  • ImmunoGen
  • Immunomedics
  • Indian Pharmaceutical Alliance
  • Innovent Biologics
  • IRIX Pharmaceuticals
  • Janssen
  • JK Pharmaceutical
  • Johnson & Johnson
  • Knowledge Transfer Network (KTN)
  • Lonza
  • Lupin
  • Marinopoulos Group
  • Matrix Laboratories
  • Medice
  • Medichem
  • Merck & Co.
  • Micron Technologies
  • Millennium
  • Mitsui & Co
  • Momenta Pharmaceuticals
  • Mylan
  • Neuland Laboratories
  • NICE Insight
  • NPS Pharmaceuticals
  • Nycomed
  • Orchid Chemicals & Pharmaceuticals
  • Oxford Biomedica
  • Patheon
  • Patheon Biologics
  • Pfizer
  • Pharmapak Technologies
  • Piramal Pharma Solutions
  • Progenics
  • Quintiles
  • Recepta Biopharma
  • Recipharm
  • Redwood Bioscience
  • Rentschler Biotechnologie
  • Roche
  • Royal DSM
  • SAFC
  • SafeBridge
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Seattle Genetics
  • Shandong Xinhua
  • ShangPharma
  • Shire
  • Siegfried AG
  • Sigmar Italia
  • SMS Pharmaceuticals
  • Solvias AG
  • Speedel
  • Stada
  • Stem CentRx
  • Stevenage Bioscience Catalyst
  • Takeda
  • Temmler Group
  • Teva API
  • Thermo Fisher Scientific
  • UMN Pharma
  • UNIGEN
  • Valeant Pharmaceuticals
  • Valerion Therapeutics, LLC.
  • Vetter Pharma-Fertigung GmbH
  • Vivante GMP Solutions
  • West Pharmaceutical Services
  • WuXi PharmaTech
  • Zhangjiang Biotech & Pharmaceutical Base Company
  • Zhejiang Jiang Yuan Tang Biotechnology

List or Organizations Mentioned in the Report:

  • Agencia Nacional de Vigilancia Sanitaria (ANVISA)
  • Asociacion Espanola de Fabricantes de Productos de Quimica Fina (AFAQUIM)
  • Associacao Brasileira da Industria Farmoquimica e de Insumos Farmaceuticos (ABIQUIFI)
  • Association of British Pharmaceutical Industry (ABPI)
  • Central Drugs Standard Control Organization (CDSCO)
  • Department of Health and Family Welfare
  • Development and Reform Commission (NDRC)
  • European Commission
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Indian Drug Manufacturer's Association (IDMA)
  • International Society of Pharmaceutical Engineering (IPSE)
  • Korea Food and Drug Administration (KFDA)
  • Korea Pharmaceutical Manufacturer's Association (KPMA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines Manufacturing Industry Partnership (MMIP)
  • Ministry of Health (MOH)
  • Ministry of Health, Labor and Welfare (MHLW)
  • Ministry of Industry and Information Technology (MIIT)
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • World Health Organization (WHO)